SERMs indeed reduce the risk of breast cancer susceptibility significantly in estrogen receptor-positive (ER+) breast cancers, but some limitations in the meta-analysis caused by variability in the duration of drug administration and disregard with respect to the ages of the subjects undergoing the clinical trial has left grounds for skepticism [7]. Here, ESR1 is linked to breast carcinoma.